Advanced Ophthalmic Drug Delivery Systems and AI-Assisted Drug Discovery: Current Progress and Future Perspectives
DOI:
https://doi.org/10.17140/phoj.2026.v11.i01.pp531-559.2643Keywords:
Ophthalmic drug delivery,, Artificial intelligence,, Ocular implants,, Nanotechnology,, 3D PrintingAbstract
Ophthalmic drug development remains one of the most challenging areas in pharmaceutical research due
to the complex anatomy and protective barriers of the eye. Conventional ocular dosage forms, particularly
topical formulations, often exhibit poor bioavailability because of rapid tear turnover, blinking, nasolacrimal
drainage, and limited corneal permeability. These limitations reduce therapeutic efficiency and necessitate
frequent dosing, ultimately affecting patient compliance. In recent years, significant advances have been
achieved in the development of innovative ocular drug delivery systems, including ocular implants, hydro-
gels, nanoparticles, nanomicelles, liposomes, microneedles, iontophoresis, in situ gels, and drug-eluting
contact lenses. These technologies aim to improve drug retention, enhance tissue penetration, and provide
sustained therapeutic effects for both anterior and posterior segment eye diseases. Simultaneously, artificial
intelligence (AI) and digital technologies are transforming ophthalmic drug discovery and development
by accelerating target identification, molecular screening, biomarker analysis, and formulation optimiza-
tion. AI-driven approaches such as machine learning, deep learning, explainable AI, and large language
models have shown considerable potential in reducing development timelines and improving predictive
accuracy. In addition, additive manufacturing technologies, including three-dimensional printing and hot-
melt extrusion, have enabled the development of personalized ophthalmic devices and customized drug
delivery systems. Despite these advances, several challenges remain, including manufacturing complexity,
regulatory uncertainties, scalability issues, data privacy concerns, and the absence of harmonized global
guidelines for AI-assisted therapeutics. This review highlights recent developments in advanced ocular drug
delivery systems, emerging AI-based technologies, regulatory perspectives, and future opportunities aimed
at improving the treatment of complex ocular diseases and reducing the global burden of visual impairment.
References
Urtti, A. (2006). Challenges and obstacles of oc-ular pharmacokinetics and drug delivery. Ad-vanced Drug Delivery Reviews, 58(11), 1131–1135. https://doi.org/10.1016/j.addr.2006.07.027
Järvinen, K., Järvinen, T., & Urtti, A. (1995). Ocular absorption following topical delivery. Advanced Drug Delivery Reviews, 16(1), 3–19. https://doi.org/10.1016/0169-409X(95)00018-6
Vidal, K. S., Suemoto, C. K., Moreno, A. B., Viana, M. C., Lotufo, P. A., Benseñor, I. M., & Brunoni, A. R. (2021). Association between posterior seg-ment eye diseases, common mental disorders, and depression: Cross-sectional and longitudi-nal analyses of Brazilian Longitudinal Study of Adult Health cohort. Journal of the Academy of Consultation-Liaison Psychiatry, 62(1), 70–78. https://doi.org/10.1016/j.jaclp.2020.07.009
Forrester, J. V., Dick, A. D., McMenamin, P. G., Roberts, F., & Pearlman, E. (2016). The eye: Ba-sic sciences in practice (4th ed.). Elsevier Health Sciences.
Zhou, R., & Caspi, R. R. (2010). Ocular im-mune privilege. F1000 Biology Reports, 2, 3. https://doi.org/10.3410/B2-3
Dosmar, E., Walsh, J., Doyel, M., Bussett, K., Oladipupo, A., Amer, S., & Goebel, K. (2022). Targeting ocular drug delivery: An examination of local anatomy and cur-rent approaches. Bioengineering, 9(2), 41. https://doi.org/10.3390/bioengineering9020041
Kels, B. D., Grzybowski, A., & Grant-Kels, J. M. (2015). Human ocular anatomy. Clinics in Dermatology, 33(2), 140–146. https://doi.org/10.1016/j.clindermatol.2014.10.006
Camburu, G., Zemba, M., Tătaru, C. P., & Purcărea, V. L. (2023). The measurement of central corneal thickness. Romanian Journal of Ophthalmology, 67(2), 168–175. https://doi.org/10.22336/rjo.2023.30
Meek, K. M., Knupp, C., Lewis, P. N., Morgan, S. R., & Hayes, S. (2024). Structural control of corneal transparency, refractive power and dynamics. Eye. Advance online publication. https://doi.org/10.1038/s41433-024-02964-0
Balla, A., Auriola, S., Grey, A. C., Demarais, N. J., Valtari, A., Heikkinen, E. M., Toropainen, E., Urtti, A., Vellonen, K. S., & Ruponen, M. (2021). Partitioning and spatial distribution of drugs in ocular surface tissues. Pharmaceutics, 13(5), 658. https://doi.org/10.3390/pharmaceutics13050658
Schoenwald, R. D., & Ward, R. L. (1978). Re-lationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. Journal of Pharmaceutical Sciences, 67(6), 786–788. https://doi.org/10.1002/jps.2600670614
Mofidfar, M., Abdi, B., Ahadian, S., Mostafavi, E., Desai, T. A., Abbasi, F., Sun, Y., Manche, E. E., Ta, C. N., & Flowers, C. W. (2021). Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies. Inter-national Journal of Pharmaceutics, 607, 120924. https://doi.org/10.1016/j.ijpharm.2021.120924
Wilson, S. E. (2020). Bowman’s layer in the cornea–Structure and function and regenera-tion. Experimental Eye Research, 195, 108033. https://doi.org/10.1016/j.exer.2020.108033
Espana, E. M., & Birk, D. E. (2020). Compo-sition, structure and function of the corneal stroma. Experimental Eye Research, 198, 108137. https://doi.org/10.1016/j.exer.2020.108137
Lagali, N., Germundsson, J., & Fagerholm, P. (2009). The role of Bowman’s layer in corneal regeneration after phototherapeutic keratectomy: A prospective study using in vivo confocal microscopy. Investigative Oph-thalmology & Visual Science, 50(9), 4192–4198. https://doi.org/10.1167/iovs.08-3294
Wilson, S. E., Torricelli, A. A. M., & Marino, G. K. (2020). Corneal epithelial basement membrane: Structure, function and regenera-tion. Experimental Eye Research, 194, 108002. https://doi.org/10.1016/j.exer.2020.108002
Germundsson, J., Karanis, G., Fagerholm, P., & La-gali, N. (2013). Age-related thinning of Bowman’s layer in the human cornea in vivo. Investiga-tive Ophthalmology & Visual Science, 54(9), 6143– 6149. https://doi.org/10.1167/iovs.13-12516
Meek, K. M., & Knupp, C. (2015). Corneal structure and transparency. Progress in Retinal and Eye Research, 49, 1–16. https://doi.org/10.1016/j.preteyeres.2015.07.001
Santana, C. P., Matter, B. A., Patil, M. A., Silva-Cunha, A., & Kompella, U. B. (2023). Corneal permeability and uptake of twenty-five drugs: Species comparison and quantitative structure-permeability relationships. Pharmaceutics, 15(6), 1646. https://doi.org/10.3390/pharmaceutics15061646
Maurice, D. M., & Mishima, S. (1984). Ocular phar-macokinetics. In M. L. Sears (Ed.), Pharmacology of the eye (pp. 19–116). Springer.
Agarwal, R., Iezhitsa, I., Agarwal, P., Ab-dul Nasir, N. A., Razali, N., Alyautdin, R., & Ismail, N. M. (2016). Liposomes in topical ophthalmic drug delivery: An update. Drug Delivery, 23(4), 1075–1091. https://doi.org/10.3109/10717544.2014.935998
Agarwal, P., & Rupenthal, I. D. (2016). Modern ap-proaches to the ocular delivery of cyclosporine A. Drug Discovery Today, 21(6), 977–988. https://doi.org/10.1016/j.drudis.2016.03.001
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009). Recent perspectives in ocular drug delivery. Pharmaceutical Research, 26(5), 1197– 1216. https://doi.org/10.1007/s11095-008-9694-
Sridhar, M. S. (2018). Anatomy of cornea and ocular surface. Indian Jour-nal of Ophthalmology, 66(2), 190–194. https://doi.org/10.4103/ijo.IJO_646_17
Joyce, N. C. (2003). Proliferative capacity of the corneal endothelium. Progress in Retinal and Eye Research, 22(3), 359–389. https://doi.org/10.1016/S1350-9462(02)00065-
Bonanno, J. A. (2012). Molecular mecha-nisms underlying the corneal endothelial pump. Experimental Eye Research, 95(1), 2–7. https://doi.org/10.1016/j.exer.2011.06.004
Fischbarg, J., & Maurice, D. M. (2004). An update on corneal hydration control. Ex-perimental Eye Research, 78(3), 537–541. https://doi.org/10.1016/j.exer.2003.09.014
Verkman, A. S. (2012). Aquaporins in clini-cal medicine. Annual Review of Medicine, 63, 303–316. https://doi.org/10.1146/annurev-med-043010-193843
Prausnitz, M. R. (1998). Permeability of cornea, sclera, and conjunctiva: A literature analy-sis for drug delivery to the eye. Journal of Pharmaceutical Sciences, 87(12), 1479–1488. https://doi.org/10.1021/js9802594
Freddo, T. F. (2013). A contemporary con-cept of the blood-aqueous barrier. Progress in Retinal and Eye Research, 32, 181–195. https://doi.org/10.1016/j.preteyeres.2012.10.002
Cunha-Vaz, J., Bernardes, R., & Lobo, C. (2011). Blood-retinal barrier. European Jour-nal of Ophthalmology, 21(Suppl. 6), S3–S9. https://doi.org/10.5301/EJO.2010.6049
Ramsay, E., Lajunen, T., Bhattacharya, M., Rein-isalo, M., Rilla, K., Kidron, H., Terasaki, T., & Urtti, A. (2023). Selective drug delivery to the retinal cells: Biological barriers and av-enues. Journal of Controlled Release, 361, 1–19. https://doi.org/10.1016/j.jconrel.2023.07.001
Abelson, M. B., Udell, I. J., & Weston, J. H. (1981). Normal human tear pH by direct measure-ment. Archives of Ophthalmology, 99(2), 301–301. https://doi.org/10.1001/archopht.1981.03930010301019
Willcox, M. D. P., Argueso, P., Georgiev, G. A., Holopainen, J. M., Laurie, G. W., Millar, T. J., Papas, E. B., Rolland, J. P., Schmidt, T. A., Stahl, U., et al. (2017). TFOS DEWS II tear film report. The Ocular Surface, 15(3), 366–403. https://doi.org/10.1016/j.jtos.2017.03.006
Pflugfelder, S. C., & Stern, M. E. (2020). Biological functions of tear film. Ex-perimental Eye Research, 197, 108115. https://doi.org/10.1016/j.exer.2020.108115
Long-term trends in human eye blink rate. (1979). PubMed. https://pubmed.ncbi.nlm.nih.gov/754827/
Grassiri, B., Zambito, Y., & Bernkop-Schnürch, A. (2021). Strategies to prolong the residence time of drug delivery sys-tems on ocular surface. Advances in Col-loid and Interface Science, 288, 102342. https://doi.org/10.1016/j.cis.2020.102342
Ducker, L., & Rivera, R. Y. (2023). Anatomy, head and neck: Eye lacrimal duct. StatPearls Publish-ing.
Agrahari, V., Mandal, A., Agrahari, V., Trinh, H. M., Joseph, M., Ray, A., Hadji, H., Mitra, R., Pal, D., & Mitra, A. K. (2016). A comprehensive in-sight on ocular pharmacokinetics. Drug Deliv-ery and Translational Research, 6(6), 735–754. https://doi.org/10.1007/s13346-016-0339-2
Ghate, D., & Edelhauser, H. F. (2008). Barriers to glaucoma drug delivery. Journal of Glaucoma, 17(2), 147–156. https://doi.org/10.1097/IJG.0b013e31815c5b2b
Sahlin, S., Laurell, C. G., Chen, E., & Philip-son, B. (1998). Lacrimal drainage capacity, age and blink rate. Orbit, 17(3), 155–159. https://doi.org/10.1076/orbi.17.3.155.2726
Agarwal, P., & Rupenthal, I. D. (2023). Non-aqueous formulations in topical ocular drug delivery—A paradigm shift? Ad-vanced Drug Delivery Reviews, 198, 114867. https://doi.org/10.1016/j.addr.2023.114867
Mishima, S., Gasset, A., Klyce, S. D., & Baum, J. L. (1966). Determination of tear volume and tear flow. Investigative Ophthalmology & Visual Sci-ence, 5(3), 264–276.
Farkouh, A., Frigo, P., & Czejka, M. (2016). Systemic side effects of eye drops: A pharmacokinetic perspective. Clinical Ophthalmology, 10, 2433–2441. https://doi.org/10.2147/OPTH.S118409
Mahaling, B., & Katti, D. S. (2016). Understanding the influence of surface properties of nanoparti-cles and penetration enhancers for improving bioavailability in eye tissues in vivo. Interna-tional Journal of Pharmaceutics, 501(1–2), 1–9. https://doi.org/10.1016/j.ijpharm.2016.01.017
Ludwig, A. (2005). The use of mucoadhe-sive polymers in ocular drug delivery. Ad-vanced Drug Delivery Reviews, 57(11), 1595–1639. https://doi.org/10.1016/j.addr.2005.07.005
Yellepeddi, V. K., Sheshala, R., McMillan, H., Gujral, C., Jones, D., & Singh, T. R. R. (2015). Punctal plug: A medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug Discovery Today, 20(7), 884–889. https://doi.org/10.1016/j.drudis.2015.02.009
Anatomy, head and neck, eye conjunctiva. (2018). PubMed. https://pubmed.ncbi.nlm.nih.gov/30137787/
Ashique, S., Mishra, N., Mohanto, S., Gowda, B. H. J., Kumar, S., Raikar, A. S., Masand, P., Garg, A., Goswami, P., & Kahwa, I. (2023). Overview of processed excipients in oc-ular drug delivery: Opportunities so far and bottlenecks. Heliyon, 10(1), e23810. https://doi.org/10.1016/j.heliyon.2023.e23810
Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014). The pathophysiology and treatment of glau-coma: A review. JAMA, 311(18), 1901–1911. https://doi.org/10.1001/jama.2014.3192
Abe, R. Y., Gracitelli, C. P. B., Diniz-Filho, A., Tatham, A. J., & Medeiros, F. A. (2015). Lamina cribrosa in glaucoma: Diagnosis and monitor-ing. Current Ophthalmology Reports, 3(2), 74–84. https://doi.org/10.1007/s40135-015-0066-8
Lu, Y., Hua, Y., Wang, B., Zhong, F., Theophanous, A., Tahir, S., Lee, P. Y., & Sigal, I. A. (2024). The ro-bust lamina cribrosa vasculature: Perfusion and oxygenation under elevated intraocular pressure. Investigative Ophthalmology & Visual Science, 65(1), 1. https://doi.org/10.1167/iovs.65.1.1
Goel, M., Picciani, R. G., Lee, R. K., & Bhattacharya, S. K. (2010). Aque-ous humor dynamics: A review. The Open Ophthalmology Journal, 4, 52–59. https://doi.org/10.2174/1874364101004010052
Acute angle-closure glaucoma. (2017). PubMed. https://pubmed.ncbi.nlm.nih.gov/28613607/
Kolko, M. (2015). Present and new treat-ment strategies in the management of glaucoma. The Open Ophthalmol-ogy Journal, 9(Suppl. 1-M5), 89–100. https://doi.org/10.2174/1874364101509010089
Tejwani, S., Machiraju, P., Nair, A. P., Ghosh, A., Das, R. K., Ghosh, A., & Sethu, S. (2020). Treatment of glaucoma by prostaglandin ag-onists and beta-blockers in combination di-rectly reduces pro-fibrotic gene expression in trabecular meshwork. Journal of Cellu-lar and Molecular Medicine, 24(9), 5195–5204. https://doi.org/10.1111/jcmm.15149
Alon, S. (2013). Selective laser trabeculoplasty: A clinical review. Journal of Current Glaucoma Practice, 7(2), 58–65. https://doi.org/10.5005/jp-journals-10008-1147
Balas, M., & Mathew, D. J. (2023). Min-imally invasive glaucoma surgery: A re-view of the literature. Vision, 7(3), 54. https://doi.org/10.3390/vision7030054
Pereira, I. C. F., van de Wijdeven, R., Wyss, H. M., Beckers, H. J. M., & den Toonder, J. M. J. (2021). Conventional glaucoma implants and the new MIGS devices: A comprehensive review of cur-rent options and future directions. Eye, 35(12), 3202–3221. https://doi.org/10.1038/s41433-021- 01408-z
Dana, R., Meunier, J., Markowitz, J. T., Joseph, C., & Siffel, C. (2020). Patient-reported bur-den of dry eye disease in the United States: Results of an online cross-sectional survey. American Journal of Ophthalmology, 216, 7–17. https://doi.org/10.1016/j.ajo.2020.03.028
Golden, M. I., Meyer, J. J., Zeppieri, M., & Patel, B. C. (2024). Dry eye syndrome. StatPearls Publish-ing.
Potvin, R., Makari, S., & Rapuano, C. J. (2015). Tear film osmolarity and dry eye disease: A review of the literature. Clinical Ophthalmology, 9, 2039–2047. https://doi.org/10.2147/OPTH.S95242
Baudouin, C., Aragona, P., Messmer, E. M., Tomlinson, A., Calonge, M., Boboridis, K. G., Akova, Y. A., Geerling, G., Labetoulle, M., & Rolando, M. (2013). Role of hyperosmolarity in the pathogenesis and management of dry eye disease: Proceedings of the OCEAN group meeting. The Ocular Surface, 11(4), 246–258. https://doi.org/10.1016/j.jtos.2013.07.003
Wei, Y., & Asbell, P. A. (2014). The core mech-anism of dry eye disease (DED) is inflamma-tion. Eye & Contact Lens, 40(4), 248–256. https://doi.org/10.1097/ICL.0000000000000042
Sheppard, J., Lee, B. S., & Periman, L. M. (2023). Dry eye disease: Identification and therapeutic strategies for primary care clinicians and clini-cal specialists. Annals of Medicine, 55(1), 241–252. https://doi.org/10.1080/07853890.2023.2166420
Ames, P., & Galor, A. (2015). Cyclosporine ophthalmic emulsions for the treatment of dry eye: A review of the clinical evi-dence. Clinical Investigation, 5(3), 267–285. https://doi.org/10.4155/cli.15.9
Qiu, W., Liu, Z., Zhang, Z., Ao, M., Li, X., & Wang, W. (2012). Punctal plugs versus artificial tears for treating dry eye: A comparative observation of their effects on contrast sensitivity. Journal of Oc-ular Biology, Diseases, and Informatics, 5(1), 19– 24. https://doi.org/10.1007/s12177-012-9098-9
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022). Diabetic macular edema: Current understand-ing, molecular mechanisms and thera-peutic implications. Cells, 11(20), 3362. https://doi.org/10.3390/cells11203362
Kowluru, R. A., & Chan, P. S. (2007). Ox-idative stress and diabetic retinopathy. Ex-perimental Diabetes Research, 2007, 43603. https://doi.org/10.1155/2007/43603
Saxena, S., Mishra, A., Saxena, A., & Natu, S. M. (2012). Advanced glycation end products and diabetic retinopathy. Journal of Ocular Bi-ology, Diseases, and Informatics, 5(3–4), 63–69. https://doi.org/10.1007/s12177-012-9104-2
Hammes, H. P. (2018). Diabetic retinopa-thy: Hyperglycaemia, oxidative stress and beyond. Diabetologia, 61(1), 29–38. https://doi.org/10.1007/s00125-017-4435-8
Lechner, J., O’Leary, O. E., & Stitt, A. W. (2017). The pathology associated with dia-betic retinopathy. Vision Research, 139, 7–14. https://doi.org/10.1016/j.visres.2017.04.003
Roy, S., Ha, J., Trudeau, K., & Beglova, E. (2010). Vascular basement membrane thickening in diabetic retinopathy. Cur-rent Eye Research, 35(12), 1045–1056. https://doi.org/10.3109/02713683.2010.518850
Penn, J. S., Madan, A., Caldwell, R. B., Bar-toli, M., Caldwell, R. W., & Hartnett, M. E. (2008). Vascular endothelial growth factor in eye disease. Progress in Reti-nal and Eye Research, 27(4), 331–371. https://doi.org/10.1016/j.preteyeres.2008.05.001
Stewart, M. W., Browning, D. J., & Landers, M. B. (2018). Current management of dia-betic tractional retinal detachments. Indian Journal of Ophthalmology, 66(12), 1751–1762. https://doi.org/10.4103/ijo.IJO_998_18
Stewart, M. W. (2017). A review of ranibizumab for the treatment of diabetic retinopathy. Ophthalmology and Therapy, 6(1), 33–47. https://doi.org/10.1007/s40123-017-0072-9
Brown, D. M., Wykoff, C. C., Boyer, D., Heier, J. S., Clark, W. L., Emanuelli, A., Higgins, P. M., Singer, M., Weinreich, D. M., Yancopoulos, G. D., et al. (2021). Evaluation of intravitreal aflibercept for the treatment of severe non-proliferative diabetic retinopathy: Results from the PANORAMA randomized clinical trial. JAMA Ophthalmology, 139(9), 946–955. https://doi.org/10.1001/jamaophthalmol.2021.2329
Arevalo, J. F., Fromow-Guerra, J., Quiroz-Mercado, H., Sanchez, J. G., Wu, L., Maia, M., Berrocal, M. H., Solis-Vivanco, A., & Farah, M. E. (2007). Primary intravitreal be-vacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Col-laborative Retina Study Group at 6-month follow-up. Ophthalmology, 114(4), 743–750. https://doi.org/10.1016/j.ophtha.2006.11.038
Romano, F., Lamanna, F., Gabrielle, P. H., Teo, K. Y. C., Battaglia Parodi, M., Iacono, P., Fraser-Bell, S., Cornish, E. E., Nassisi, M., Viola, F., et al. (2023). Update on retinal vein occlusion. Asia-Pacific Journal of Ophthalmology, 12(3), 196–210. https://doi.org/10.1097/APO.0000000000000571
Haller, J. A., Tomaiuolo, M., Lucas, M. M., Yang, C. C., Hyman, L., Lee, A. Y., Lee, C. S., Van Gelder, R., Lorch, A., Miller, J. W., et al. (2024). Disparities in retinal vein occlusion presentation and initiation of anti-VEGF therapy: An Academy IRIS® Registry analysis. Ophthalmology Retina, 8(7), 657–665. https://doi.org/10.1016/j.oret.2024.01.012
Browning, D. J. (2012). Retinal vein occlusions: Evidence-based management. Springer.
Labay-Tejado, S., Menendez-Acebal, C., Bernal-Morales, C., Alforja, S., & Zarranz-Ventura, J. (2023). Central retinal vein occlusion. In Retinal and choroidal vascular diseases of the eye (pp. 165–177). Academic Press. https://doi.org/10.1016/B978-0-323-85737- 8.00010-2
Hang, A., Feldman, S., Amin, A. P., Ochoa, J. A. R., & Park, S. S. (2023). Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals, 16(8), 1140. https://doi.org/10.3390/ph16081140
Uveitis. (2019). PubMed. https://pubmed.ncbi.nlm.nih.gov/31082037/
González, M. M., Solano, M. M., Porco, T. C., Oldenburg, C. E., Acharya, N. R., Lin, S. C., & Chan, M. F. (2018). Epidemiology of uveitis in a US population-based study. Journal of Ophthalmic Inflammation and Infection, 8(1), 6. https://doi.org/10.1186/s12348-018-0145-2
Forrester, J. V., Kuffova, L., & Dick, A. D. (2018). Au-toimmunity, autoinflammation, and infection in uveitis. American Journal of Ophthalmology, 189, 77–85. https://doi.org/10.1016/j.ajo.2018.02.019
Eskandarpour, M., Nunn, M. A., Weston-Davies, W., & Calder, V. L. (2021). Immune-mediated retinal vasculitis in posterior uveitis and experimental models: The leukotriene B4-VEGF axis. Cells, 10(2), 396. https://doi.org/10.3390/cells10020396
Tomkins-Netzer, O., Niederer, R., Green-wood, J., Fabian, I. D., Serlin, Y., Friedman, A., & Lightman, S. (2024). Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy. Progress in Retinal and Eye Research, 99, 101245. https://doi.org/10.1016/j.preteyeres.2023.101245
Relationship between aqueous humor protein level and outflow facility in patients with uveitis. (n.d.). Investigative Ophthalmology & Visual Sci-ence. https://iovs.arvojournals.org/article.aspx? articleid=2200090
McHarg, M., Young, L. A., Kesav, N., Yakin, M., Sen, H. N., & Kodati, S. (2022). Practice patterns regarding regional corticosteroid treatment in noninfectious uveitis: A survey study. Journal of Ophthalmic Inflammation and Infection, 12(1), 3. https://doi.org/10.1186/s12348-021-00275-z
Wu, X., Tao, M., Zhu, L., Zhang, T., & Zhang, M. (2023). Pathogenesis and current thera-pies for non-infectious uveitis. Clinical and Experimental Medicine, 23(4), 1089–1104. https://doi.org/10.1007/s10238-022-00854-0
Rein, D. B., Wittenborn, J. S., Burke-Conte, Z., Gulia, R., Robalik, T., Ehrlich, J. R., Lundeen, E. A., & Flaxman, A. D. (2022). Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmology, 140(12), 1202–1208. https://doi.org/10.1001/jamaophthalmol.2022.4409
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021). Age-related macular degeneration. Nature Reviews Disease Primers, 7(1), 31. https://doi.org/10.1038/s41572-021-00265-2
Somasundaran, S., Constable, I. J., Mellough, C. B., & Carvalho, L. S. (2020). Retinal pigment ep-ithelium and age-related macular degeneration: A review of major disease mechanisms. Clinical & Experimental Ophthalmology, 48(8), 1043–1056. https://doi.org/10.1111/ceo.13836
Heesterbeek, T. J., Lorés-Motta, L., Hoyng, C. B., Lechanteur, Y. T. E., & den Hollan-der, A. I. (2020). Risk factors for progression of age-related macular degeneration. Oph-thalmic and Physiological Optics, 40(2), 140–170. https://doi.org/10.1111/opo.12675
Wong, J. H. C., Ma, J. Y. W., Jobling, A. I., Bran-dli, A., Greferath, U., Fletcher, E. L., & Vessey, K. A. (2022). Exploring the pathogenesis of age-related macular degeneration: A review of the interplay between retinal pigment epithe-lium dysfunction and the innate immune sys-tem. Frontiers in Neuroscience, 16, 1009599. https://doi.org/10.3389/fnins.2022.1009599
Wet age-related macular degen-eration (AMD). (2021). PubMed. https://pubmed.ncbi.nlm.nih.gov/34283513/
Galindo-Camacho, R. M., Blanco-Llamero, C., da Ana, R., Fuertes, M. A., Señoráns, F. J., Silva, A. M., García, M. L., & Souto, E. B. (2022). Therapeutic approaches for age-related macular degeneration. International Journal of Molecular Sciences, 23(19), 11769. https://doi.org/10.3390/ijms231911769
Sato-Akushichi, M., Ono, S., Taneda, T., Klose, G., Sasamori, A., & Song, Y. (2022). One-year outcome of combination therapy with full or reduced photodynamic therapy and one anti-vascular endothelial growth factor in pachy-choroid neovasculopathy. Pharmaceuticals, 15(4), 483. https://doi.org/10.3390/ph15040483
Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., et al. (2023). Advances in drug delivery systems, challenges and future directions. Heliyon, 9(6), e17488. https://doi.org/10.1016/j.heliyon.2023.e17488
Al Fatease, M., Alany, A., Abdelkader, R. G., Otero-Espinar, J., Arango-Gonzalez, B., Mostafa, M., Alany, R. G., & Abdelkader, H. (2023). Recent advances of ocular drug delivery systems: Prominence of ocular implants for chronic eye diseases. Pharmaceutics, 15(6), 1746. https://doi.org/10.3390/pharmaceutics15061746
Short, B. G. (2008). Safety evaluation of ocular drug delivery formulations: Techniques and practical considera-tions. Toxicologic Pathology, 36(1), 49–62. https://doi.org/10.1177/0192623307310946
U.S. Food and Drug Administration. (2024). Orange book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-preface
Mohan, S., & Ratra, D. (2023). Intravitreal im-plants. StatPearls Publishing.
Smith, T. J., Pearson, P. A., Blandford, D. L., Brown, J. D., Goins, K. A., Hollins, J. L., Schmeisser, E. T., Glavinos, P., Baldwin, L. B., & Ashton, P. (1992). In-travitreal sustained-release ganciclovir. Archives of Ophthalmology, 110(2), 255–258. https://doi.org/10.1001/archopht.1992.01080140117037
Yasukawa, T., Ogura, Y., Kimura, H., Sakurai, E., & Tabata, Y. (2006). Drug delivery from ocular im-plants. Expert Opinion on Drug Delivery, 3(2), 261– 273. https://doi.org/10.1517/17425247.3.2.261
Khalil, I. A., Ali, I. H., & El-Sherbiny, I. M. (2019). Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: In vitro, ex vivo and in vivo evaluation. Nanomedicine, 14(1), 33–55. https://doi.org/10.2217/nnm-2018-0182
Wu, Y., Liu, Y., Li, X., Kebebe, D., Zhang, B., Ren, J., Lu, J., Li, J., Du, S., & Liu, Z. (2019). Research progress of in-situ gelling ophthalmic drug delivery system. Asian Jour-nal of Pharmaceutical Sciences, 14(1), 1–15. https://doi.org/10.1016/j.ajps.2018.04.008
Ding, X., Ben-Shlomo, G., & Que, L. (2020). Soft contact lens with embedded microtubes for sustained and self-adaptive drug deliv-ery for glaucoma treatment. ACS Applied Materials & Interfaces, 12(41), 45789–45795. https://doi.org/10.1021/acsami.0c13295
Xu, J., Ge, Y., Bu, R., Zhang, A., Feng, S., Wang, J., Gou, J., Yin, T., He, H., Zhang, Y., et al. (2019). Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glau-coma. Journal of Controlled Release, 305, 18–28. https://doi.org/10.1016/j.jconrel.2019.05.008
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Public Health - Open Journal (PHOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
